Precipio Inc. (PRPO)

0.9001 +0.4234 (+88.819%)

IEX Real-Time Price

March 20, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 0.4767

Price Open 0.4988

Volume: 26.03M

Avg Volume: 1.17M

Market Cap: 11.46M

P/E Ratio -

52 Wk Range 0.4601-28.16

PRPO Earning Report

Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

Q4 2016
0.00 (0)


Precipio's (PRPO) CEO Ilan Danieli on Q3 2017 Results - Earnings Call Transcript (2017-11-21 13:28 SeekingAlpha)

Precipio, Inc. (PRPO) Q3 2017 Earnings Conference Call November 21, 2017 9:00 AM ET Executives Scott Gordon President-CORE IR Ilan Danieli Chief Executive Officer Carl Iberger Chief Financial Officer Analysts Presentation Operator Good mor…


Precipio reports Q3 results (2017-11-20 16:07 SeekingAlpha)

Precipio (NASDAQ: PRPO ): Q3 EPS of -$1.36 Revenue of $0.27M (-27.0% Y/Y) Press Release More news on: Precipio, Inc., Earnings news and commentary, Tech stocks news, ,


Precipio readies $6M equity offering, shares down 47% (2017-08-23 12:07 SeekingAlpha)

Thinly traded nano cap Precipio ( PRPO -47.1% ) slumps on a 26x surge in volume, albeit on turnover of only 340K shares, in response to its planned public offering of 6,000 Units at $1,000 per Unit. More news on: Precipio, Inc., Healthcare stocks news, Stocks on the move, Read more…


Precipio Diagnostics and Transgenomic Complete Merger (2017-06-30 07:00 Business Wire)

Company Renamed Precipio, Inc.--To Commence Trading On NASDAQ Under The New Ticker "PRPO" Precipio Diagnostics, LLC and Transgenomic Inc. (OTCQB: TBIOD) today announced the closing of their previously announced merger. In connection with the transaction, Transgenomic has changed its n…


Transgenomic Prepares for Planned Relisting On NASDAQ (2017-06-21 07:30 Business Wire)

Transgenomic Inc. (OTCQB:TBIOD) today announced that it is advancing its previously announced plans for relisting on the NASDAQ Capital Market. After receiving shareholder approval, the company implemented a reverse split of its shares on June 13, 2017, in order to meet NASDAQ relisting requ…


Precipio and Transgenomic Announce Experts from Yale and Harvard Joining New Scientific Advisory Board to Support Merged Company's Growth Initiatives (2017-06-16 08:00 Business Wire)

Distinguished Experts in Disease Diagnosis and Diagnostics Technology Bring World Class Scientific Acumen and Insight to Help Guide the New Merged Companys Expansion and Growth Other Recent Pre-Merger Developments Include EPO Decision to Grant Patent Protection in Europe for Tr…



Shares Outstanding: 12.73M

Top 15 Institution Percent: 0.90

Price To Sales: 8.67

Price To Book: 0.33

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -133.08

Return On Equity: -2765.57

Profit Margin: N/A

Price History

Beta: -0.05

50-day Moving Avg: 0.89

200-day Moving Avg: 3.33

YTD Change: -21.73

5-day Change: 63.65

1-month Change: 25.01

3-month Change: -16.66

6-month Change: -52.87

1-year Change: -95.00

Revenue Per Share: 0.00

Revenue Per Employee: 0.00


Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -

Company Profile

Name: Precipio Inc.

Exchange: NASDAQ Capital Market

Industry: Medical Diagnostics & Research

Sector: Healthcare


Precipio Inc is a diagnostics company, which has built a platform designed to eradicate the problem of misdiagnosis by harnessing the expertise and technology developed within academic institutions and delivering diagnostic information to physicians.